Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | BRAF class 1 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
BRAF class 1 | melanoma | predicted - sensitive | Exarafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Exarafenib (KIN-2787) treatment led to inhibition of tumor growth in a melanoma cell line xenograft model harboring a BRAF class 1 mutation (J of Clin Oncol 39, no. 15_suppl (May 20, 2021) 3116-3116). | detail... | |
BRAF class 1 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 1 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... | |
BRAF class 1 | Advanced Solid Tumor | predicted - sensitive | Exarafenib | Case Reports/Case Series | Actionable | In a Phase I trial, Exarafenib (KIN-2787) was tolerated and resulted in a partial response in 17.6% (6/34) and stable disease in 23.5% (8/34) of patients with BRAF-driven advanced solid tumors or NRAS-driven melanoma, including 3 partial responses in patients harboring BRAF class 1 mutations (Cancer Res (2023) 83 (8_Supplement): CT032; NCT04913285). | detail... | |
BRAF class 1 | Advanced Solid Tumor | predicted - sensitive | DCC-3084 | Preclinical - Cell culture | Actionable | In a preclinical study, DCC-3084 inhibited downstream signaling and proliferation in cells expressing a BRAF class 1 mutation in culture (Cancer Res (2023) 83 (7_Supplement): 4045). | detail... |